Maternal vaccination with RSVpreF and risk of hypertensive disorders of pregnancy: a systematic review and meta-analysis.
VaccineAug 29, 2026 (epub)
Clinical ResearchObstetrics & Gynecology
Abdallah Alami, Meghan Lewis, Darine El-Chaâr et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the association between maternal RSVpreF vaccination and hypertensive disorders of pregnancy (HDP) in 148,267 participants across nine studies. The analysis found a statistically significant increase in overall HDP risk (RR 1.08, 95% CI 1.02-1.13; p=0.004), primarily driven by observational studies, with gestational hypertension being the main contributor.
Key findings
- Maternal RSVpreF vaccination was associated with a small increase in overall HDP risk (RR 1.08, 95% CI 1.02-1.13; p=0.004).
- The increase in HDP risk was primarily driven by observational studies (RR 1.08, 95% CI 1.02-1.14).
- RCTs showed a directionally consistent but non-significant RR of 1.12 (95% CI 0.87-1.43).
- No significant association was found for preeclampsia/eclampsia.
Why it matters
Understanding the potential risks associated with maternal vaccination is crucial for clinicians to make informed decisions and engage in shared decision-making with patients, especially given the substantial benefits of preventing infant RSV disease.